AstraZeneca (NYSE:AZN) Hits New 12-Month High at $48.83
AstraZeneca plc (NYSE:AZN) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $48.83 and last traded at $48.83, with a volume of 7843500 shares changing hands. The stock had previously closed at $43.27.
Several analysts have recently issued reports on the stock. DZ Bank lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Tuesday, September 3rd. ValuEngine lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Argus lifted their target price on shares of AstraZeneca to $50.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Four investment analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $45.96.
The company’s 50-day moving average price is $44.30 and its 200-day moving average price is $41.16. The firm has a market cap of $113.53 billion, a price-to-earnings ratio of 24.88, a price-to-earnings-growth ratio of 1.44 and a beta of 0.49. The company has a quick ratio of 0.75, a current ratio of 0.95 and a debt-to-equity ratio of 1.19.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Manchester Financial Inc. acquired a new position in AstraZeneca during the second quarter worth about $25,000. Oakworth Capital Inc. boosted its position in AstraZeneca by 141.0% during the second quarter. Oakworth Capital Inc. now owns 964 shares of the company’s stock worth $40,000 after acquiring an additional 564 shares during the last quarter. San Francisco Sentry Investment Group CA boosted its position in AstraZeneca by 37.6% during the second quarter. San Francisco Sentry Investment Group CA now owns 967 shares of the company’s stock worth $40,000 after acquiring an additional 264 shares during the last quarter. Winslow Evans & Crocker Inc. boosted its position in AstraZeneca by 58.6% during the second quarter. Winslow Evans & Crocker Inc. now owns 1,050 shares of the company’s stock worth $44,000 after acquiring an additional 388 shares during the last quarter. Finally, Legacy Advisors LLC acquired a new position in AstraZeneca during the second quarter worth about $48,000. Hedge funds and other institutional investors own 17.68% of the company’s stock.
AstraZeneca Company Profile (NYSE:AZN)
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: S&P 500 Index
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.